A Single Centre Prospective, Randomized, Double Blind, Crossover, Pharmacokinetic, Safety and Tolerability Study to Compare Long-term Infusion Administration of LDLL600 Against Esmolol in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 22 Apr 2013
At a glance
- Drugs Landiolol (Primary) ; Esmolol
- Indications Coronary disorders; Hypertension; Supraventricular tachycardia
- Focus Adverse reactions; Pharmacokinetics
- 09 Jan 2013 New trial record
- 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.